PeptideDB

XMU-MP-3 2031152-08-4

XMU-MP-3 2031152-08-4

CAS No.: 2031152-08-4

XMU-MP-3 is a potent non-covalent BTK inhibitor (antagonist) with IC50s of 10.7 nM and 17.0 nM for BTK WT and BTK C481S
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

XMU-MP-3 is a potent non-covalent BTK inhibitor (antagonist) with IC50s of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutant in the presence of 10 μM ATP, respectively. XMU-MP-3 also causes apoptosis.

Physicochemical Properties


Molecular Formula C27H27F3N8O
Molecular Weight 536.551494836807
Exact Mass 536.225
CAS # 2031152-08-4
PubChem CID 122648639
Appearance Light yellow to brown solid powder
LogP 5.2
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 10
Rotatable Bond Count 5
Heavy Atom Count 39
Complexity 848
Defined Atom Stereocenter Count 0
InChi Key MCEWMWAJAOMTBE-UHFFFAOYSA-N
InChi Code

InChI=1S/C27H27F3N8O/c1-16-8-9-21(32-25(39)18-6-5-7-20(11-18)27(28,29)30)12-22(16)38-14-19-13-31-26(34-24(19)36(3)15-38)33-23-10-17(2)35-37(23)4/h5-13H,14-15H2,1-4H3,(H,32,39)(H,31,33,34)
Chemical Name

N-[3-[2-[(2,5-dimethylpyrazol-3-yl)amino]-8-methyl-5,7-dihydropyrimido[4,5-d]pyrimidin-6-yl]-4-methylphenyl]-3-(trifluoromethyl)benzamide
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets IC50: 10.7 nM (BTK WT), 17.0 nM (BTK C481S), Apoptosis[1]
ln Vitro XMU-MP-3 suppresses the growth of BTK-transformed Ba/F3 cells with a 48-hour half-life of 0.001–10,000 nM [1]. Ramos, JeKo-1, and NALM-6 are all inhibited by XMU-MP-3 (1–1000 nM), with IC50 values of 326.6 nM, 685.6 nM, and 1065 nM, respectively[1]. -cells Ba/F3 [1]. Ba/F3 cells from BTK (C481S) undergo apoptosis when exposed to XMU-MP-3 at 5000 nM[1]. In Ba/F3 cells transfected with BTK, there is dose-dependent auto- and transphosphorylation of BTK at the Y223 and Y551 sites[1].
ln Vivo In mouse xenograft models, XMU-MP-3 (25 and 50 mg/kg) significantly inhibits tumor growth[1].
Cell Assay Cell Proliferation Assay[1]
Cell Types: BTK-transformed and parental Ba/F3 cells
Tested Concentrations: 0.001, 0.01, 0.1, 1, 10, 100, 1000, 10000 nM
Incubation Duration: 48 hrs (hours)
Experimental Results: Inhibited BTK-transformed Ba/F3 cell proliferation with an IC50 of 11.4 nM, while it demonstrated negligible anti-proliferative effects on parental wild-type Ba/F3 cells (IC50 >10000 nM).

Western Blot Analysis[1]
Cell Types: BTK-transformed Ba/F3 cells
Tested Concentrations: 10, 50, 100, 500, 1000 nM
Incubation Duration: 4 hrs (hours)
Experimental Results: The phosphorylation levels of BTK Y223 and Y551 were Dramatically decreased at concentrations as low as 100 nM, and completely suppressed at the concentration of 1000 nM.
Animal Protocol Animal/Disease Models: Nu/nu BALB/ c mice (4-6 weeks of age) bearing BTK-transformed Ba/F3 and Ramos xenograft models[1]
Doses: 25 and 50 mg/kg
Route of Administration: Treated by tail vein injection; the injection volume was 0.1 mL per 10 g; daily for 14 days
Experimental Results: Dramatically diminished the tumor size without affecting animal weights.
References

[1]. A Non-Covalent Inhibitor XMU-MP-3 Overrides Ibrutinib-Resistant Btk C481S Mutation in B-cell Malignancies. Br J Pharmacol. 2019 Dec;176(23):4491-4509.


Solubility Data


Solubility (In Vitro) DMSO : 100 mg/mL (186.38 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.8638 mL 9.3188 mL 18.6376 mL
5 mM 0.3728 mL 1.8638 mL 3.7275 mL
10 mM 0.1864 mL 0.9319 mL 1.8638 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.